Journal
JOURNAL OF HEPATOLOGY
Volume 60, Issue 3, Pages 643-653Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2013.09.016
Keywords
Beta blockers; Portal hypertension; Variceal hemorrhage; Cirrhosis; Ascites
Categories
Ask authors/readers for more resources
Cirrhosis is a leading cause of death in the United States and worldwide. Beta-blockers have been established in numerous studies as part of the cornerstone of the medical management of cirrhosis, particularly in the primary and secondary prevention of variceal hemorrhage. However, new evidence has cautioned the use of beta-blockers in patients with end-stage cirrhosis and refractory ascites. In this article, we review the beneficial effects of beta-blocker therapy, the potential harms of aggressive beta-blocker therapy, and provide suggestions regarding the appropriate use of this class of medications in patients with cirrhosis. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available